Quality of life in ovarian cancer

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 50, Issue 6, 2005, Pages 407-416

  Penson, Richard ^a   Cella, David ^b   Wenzel, Lari ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

Ovarian cancer; Ovarian carcinoma; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER DIAGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CHRONIC DISEASE; CONFERENCE PAPER; HAIR LOSS; HUMAN; INTESTINE OBSTRUCTION; OVARY CANCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; REMISSION;

CAREGIVERS; FAMILY; FEMALE; HEALTH STATUS INDICATORS; HUMANS; OVARIAN NEOPLASMS; PSYCHOMETRICS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS;

EID: 20844451581     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (72)

1. Edwards BK, Howe HL, Ries LA, et al: Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 2002; 94:2766-2792
2. Cannistra SA: Cancer of the ovary. N Engl J Med 1993;329: 1550-1559
3. Kornblith AB, Thaler HT, Wong G, et al: QOL of women with ovarian cancer. Gynecol Oncol 1995;59:231-242
4. Markman M: The myth of measurable disease in ovarian cancer. J Clin Oncol 2003;21:3013-3015
5. Armstrong DK: Relapsed ovarian cancer: Challenges and management strategies for a chronic disease. Oncologist (suppl 5) 2002;7:20-28
6. Cella DF, Tulsky DS: Measuring QOL today: Methodological aspects. Oncology (Huntingt) 1990;4:29-38; discussion 69
7. Bottomley A: The cancer patient and QOL. Oncologist 2002;7:120-125
8. Velikova G, Stark D, Selby P: QOL instruments in oncology. Eur J Cancer 1999;35:1571-1580
9. van Knippenberg FC, de Haes JC: Measuring the QOL of cancer patients: psychometric properties of instruments. J Clin Epidemiol 1988;41:1043-1053
10. Schumacher M, Olschewski M, Schulgen G: Assessment of QOL in clinical trials. Stat Med 1991;10:1915-1930
11. Bodurka-Bevers D, Basen-Engquist K, Carmack CL, et al: Depression, anxiety, and QOL in patients with epithelial ovarian cancer. Gynecol Oncol 2000;78:302-308
12. Gotay CC, Korn EL, McCabe MS, et al: Quality-of-life assessment in cancer treatment protocols: Research issues in protocol development. J Natl Cancer Inst 1992;84:575-579
13. Schipper H, Clinch J: Assessment of treatment of cancer. In Measuring Health: A Practical Approach. Edited by G Smith. New York, John Wiley & Sons, 1988, pp 109-139
14. Calman KC: QOL in cancer patients: An hypothesis. J Med Ethics 1984;10:124-127
15. Study protocol for the World Health Organization project to develop a QOL assessment instrument (WHOQOL). Qual Life Res 1993;2:153-159
16. Karnofsky D, Burchenal J: The clinical evaluation of chemotherapeutic agents in cancer. In Evaluation of chemotherapeutic agents. Edited by C MacLeod. New York, Columbia University Press, 1949, pp 199-205
17. Slevin ML, Plant H, Lynch D, et al: Who should measure QOL, the doctor or the patient? Br J Cancer 1988;57:109-112
18. Maguire P, Selby P: Assessing QOL in cancer patients. Br J Cancer 1989;60:437-440
19. Burris HA 3rd, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413
20. Gelber RD, Goldhirsch A, Cavalli F: Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer: The International Breast Cancer Study Group. Ann Intern Med 1991;114:621-628
21. Parmar MK, Ledermann JA, Colombo N, et al: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099-2106
22. Vasey PA, Jayson GC, Gordon A, et al: Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004;96:1682-1691
23. Gralla RJ: Silk purse in Atlanta: A commentary on SWOG 9509, an advanced non-small cell lung cancer trial. Oncologist 1999;4:188-190
24. Ozols RF, Bundy BN, Greer BE, et al: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2003; 21:3194-3200
25. Cella D, Paul D, Yount S, et al: What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Invest 2003;21:526-535
26. Demetri GD, Kris M, Wade J, et al: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study: Procrit Study Group. J Clin Oncol 1998;16:3412-3425
27. Derogatis LR, Morrow GR, Fetting J, et al: The prevalence of psychiatric disorders among cancer patients. JAMA 1983; 249:751-757
28. Groenvold M: Methodological issues in the assessment of health-related QOL in palliative care trials. Acta Anaesthesiol Scand 1999;3:948-953
29. Chochinov HM, Wilson KG, Enns M, et al: "Are you depressed?" Screening for depression in the terminally ill. Am J Psychiatr 1997;154:674-676
30. Lutgendorf SK, Anderson B, Ullrich P, et al: QOL and mood in women with gynecologic cancer: A one year prospective study. Cancer 2002;94:131-140
31. Buchholz WM: A piece of my mind: HOPE. JAMA 1990;263: 2357-2358
32. Emanuel EJ, Fairclough DL, Slutsman J, et al: Assistance from family members, friends, paid care givers, and volunteers in the care of terminally ill patients. N Engl J Med 1999;341:956-963
33. Kaye JM, Gracely EJ: Psychological distress in cancer patients and their spouses. J Cancer Educ 1993;8:47-52
34. Dar R, Beach CM, Barden PL, et al: Cancer pain in the marital system: A study of patients and their spouses. J Pain Symptom Manage 1992;7:87-93
35. Andersen BL, Anderson B, deProsse C: Controlled prospective longitudinal study of women with cancer: II. Psychological outcomes. J Consult Clin Psychol 1989;57:692-697
36. Zacharias DR, Gilg CA, Foxall MJ: QOL and coping in patients with gynecologic cancer and their spouses. Oncol Nurs Forum 1994;21:1699-1706
37. Guidozzi F: Living with ovarian cancer. Gynecol Oncol 1993;50:202-207
38. Wenzel L, Donnelly J, Fowler J, et al: Resilience, reflection, and residual stress in ovarian cancer survivorship: A GOG study. Psycho-Oncology 2002;11:142-154
39. Lakusta CM, Atkinson MJ, Robinson JW, et al: QOL in ovarian cancer patients receiving chemotherapy. Gynecol Oncol 2001;81:490-495
40. Wenzel L, Vergote I, Cella D: QOL in patients receiving treatment for gynecologic malignancies: Special considerations for patient care. Int J Gynaecol Obstet (suppl) 2003;831:211-229
41. Coates A, Gebski V, Signorini D, et al: Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer: Australian New Zealand Breast Cancer Trials Group. J Clin Oncol 1992;10:1833-1838
42. Smith TJ, Staats PS, Deer T, et al: Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 2002;20:4040-4049
43. Lang EV, Benotsch EG, Fick LJ, et al: Adjunctive non-pharmacological analgesia for invasive medical procedures: A randomised trial. Lancet 2000;55:1486-9140
44. Spiegel D: Mind matters: Group therapy and survival in breast cancer. N Engl J Med 2001;345:1767-1768
45. Ruo B, Rumsfeld JS, Hlatky MA, et al: Depressive symptoms and health-related QOL: The Heart and Soul Study. JAMA 2003;290:215-221
46. Wenzel L, Monk B, Huang H, et al: Clinically meaningful quality-of-life changes in ovarian cancer: Results from Gynecologic Oncology Group Clinical Trial 152 (abstr). Clin Ther (suppl D) 2003;25:D26-D27
47. Cella DF, Tulsky DS, Gray G, et al: The functional assessment of cancer therapy scale: Development and validation of the general measure. J Clin Oncol 1993;11:570-579
48. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, et al: Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol 2001;19:1809-1817
49. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376
50. Cull A, Howat S, Greimel E, et al: Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the QOL of ovarian cancer patients in clinical trials: A progress report. Eur J Cancer 2001;37:47-53
51. Hjermstad MJ, Fossa SD, Bjordal K, et al: Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire. J Clin Oncol 1995;13:1249-1254
52. Cohen SR, Mount BM: Living with cancer: "good" days and "bad" days: What produces them? Can the McGill QOL questionnaire distinguish between them? Cancer 2000;89: 1854-1865
53. Littlewood TJ, Bajetta E, Nortier JW, et al: Effects of epoetin alfa on hematologic parameters and QOL in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874
54. Doyle C, Crump M, Pintilie M, et al: Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 2001;19:1266-1274
55. Markman M: Consolidation/maintenance chemotherapy for ovarian cancer. Curr Oncol Rep 2003;5:454-458
56. Slevin ML: QOL: Philosophical question or clinical reality? BMJ 1992;305:466-469
57. Donovan KA, Greene PG, Shuster JL, et al: Treatment preferences in recurrent ovarian cancer. Gynecol Oncol 2002;86: 200-211
58. Detmar SB, Muller MJ, Wever LD, et al: The patient-physician relationship: Patient-physician communication during outpatient palliative treatment visits: An observational study. JAMA 2001;285:1351-1357
59. Detmar SB, Muller MJ, Schornagel JH, et al: Role of health-related QOL in palliative chemotherapy treatment decisions. J Clin Oncol 2002;20:1056-1062
60. Levine MN, Ganz PA: Beyond the development of quality-of-life instruments: Where do we go from here? J Clin Oncol 2002;20:2215-2216
61. Browman GP: Science, language, intuition, and the many meanings of QOL. J Clin Oncol 1999;17:1651-1653
62. Efficace F, Bottomley A, Osoba D, et al: Beyond the development of health-related quality-of-life (HRQOL) measures: A checklist for evaluating HRQOL outcomes in cancer clinical trials: Does HRQOL evaluation in prostate cancer research inform clinical decision making? J Clin Oncol 2003;21:3502-3511
63. Curran D, Molenberghs G, Aaronson NK, et al: Analysing longitudinal continuous QOL data with dropout. Stat Methods Med Res 2002;11:5-23
64. Lederberg M, Fitchett G: Can you measure a sunbeam with a ruler? Psycho-oncol 1999;8:375-377
65. Dalrymple JL, Levenback C, Wolf JK, et al: Trends among gynecologic oncology inpatient deaths: Is end-of-life care improving? Gynecol Oncol 2002;85:356-361
66. Weeks JC, Cook EF, O'Day SJ, et al: Relationship between cancer patients' predictions of prognosis and their treatment preferences. Jama 1998;279:1709-1714
67. Smith TJ, Swisher K: Telling the truth about terminal cancer. JAMA 1998;279:1746-1748
68. Stephens RJ, Hopwood P, Girling DJ, et al: Randomized trials with QOL endpoints: Are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings? Qual Life Res 1997;6:225-236
69. Coates A, Gebski V, Bishop JF, et al: Improving the QOL during chemotherapy for advanced breast cancer: A comparison of intermittent and continuous treatment strategies. N Engl J Med 1987;317:1490-1495
70. Weeks J: Measurement of utilities and quality-adjusted survival. Oncology (Huntingt) 1995;9:67-70
71. Cella D: What do global quality-of-life questions really measure? Insights from Hobday et al and the "do something" rule. J Clin Oncol 2003;21:3178-3179; author reply 3179
72. Ferrell B, Smith SL, Cullinane CA, et al: Psychological well being and QOL in ovarian cancer survivors. Cancer 2003;98:1061-1071